Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Mesial Temporal Lobe Epilepsy
In brief
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Key facts
- Study ID
- NCT05135091
- Run by
- Neurona Therapeutics
- People needed
- 88
- Starts
- 2022-06-16
- Expected to finish
- 2043-09-01
- Last updated by the study team
- 2026-06-09
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama — Birmingham, Alabama, United States (enrolling)
- Mayo Clinic Arizona Epilepsy Center — Phoenix, Arizona, United States (enrolling)
- Banner-University of Arizona Medical Center Tucson Comprehensive Epilepsy Program — Tucson, Arizona, United States (enrolling)
- University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States (enrolling)
- University of Southern California Keck Hospital — Los Angeles, California, United States (enrolling)
- University of California Los Angeles — Los Angeles, California, United States (enrolling)
- UC Irvine Medical Center — Orange, California, United States (enrolling)
- Stanford University — Palo Alto, California, United States (enrolling)
- University of California Davis — Sacramento, California, United States (enrolling)
- University of California San Diego — San Diego, California, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)
- George Washington University — Washington D.C., District of Columbia, United States (enrolling)
- University of Miami — Miami, Florida, United States (enrolling)
- Rush University Medical Center — Chicago, Illinois, United States (enrolling)
- University of Chicago — Chicago, Illinois, United States (enrolling)
- University of Iowa Health Care — Iowa City, Iowa, United States (enrolling)
- Ochsner Clinic Foundation — New Orleans, Louisiana, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Wayne State University/Detroit Medical Center Comprehensive Epilepsy Program — Detroit, Michigan, United States (enrolling)
- Washington University at St. Louis — St Louis, Missouri, United States (enrolling)
- Dartmouth Hitchcock Medical Center/ Department of Neurology — Lebanon, New Hampshire, United States (enrolling)
- Hofstra Northwell Comprehensive Epilepsy Center — Great Neck, New York, United States (enrolling)
- NYU Langone Comprehensive Epilepsy Center — New York, New York, United States (enrolling)
- SUNY Upstate Medical University — Syracuse, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.